The FDA has approved oveporexton (Orzeyful; Takeda), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. The agency’s decision, announced August 5, 2026, positions oveporexton as the first therapy indicated to address the underlying orexin deficiency that drives NT1, rather than managing its symptoms individually.
First-in-Class Mechanism Targets Orexin Deficiency
NT1 is a rare, chronic neurological disease caused by a loss of orexin-producing neurons, affecting an estimated 120,000 people in the US. The condition produces a persistent, 24-hour symptom burden that includes excessive daytime sleepiness, cataplexy, cognitive symptoms, and disrupted nighttime sleep, with effects that extend into work, education, and social functioning.
Oveporexton selectively stimulates OX2R to restore orexin signaling, promoting wakefulness and reducing abnormal rapid eye movement (REM) sleep phenomena, including cataplexy. Takeda characterizes the approval as the introduction of an entirely new drug class for the field.
Related: Global Study Assesses Leukemia Care Needs
Phase 3 Program Shows Broad Symptom Improvement
The approval was supported by the global phase 3 FirstLight and RadiantLight trials, which demonstrated statistically significant improvements across the full symptom range of NT1, including excessive daytime sleepiness, cataplexy, and health-related quality of life, compared with placebo. Oveporexton was generally well tolerated, with a safety profile consistent across the clinical program; the most common adverse effects were insomnia, urinary urgency, urinary frequency, and excessive salivation.
Additional analyses of the FirstLight and RadiantLight data presented at the SLEEP 2026 Annual Meeting in June expanded on these findings. Polysomnography data from 157 FirstLight and 101 RadiantLight participants showed that oveporexton normalized REM sleep architecture, including longer REM latency, less time spent in REM during the first quarter of the night, and fewer NT1-specific REM transitions, alongside reductions in total REM percentage.
Emmanuel Mignot, MD, PhD, principal US investigator for the Orzeyful phase 3 program, stated that as the first and only approved orexin therapy to treat the broad spectrum of the disease, Orzeyful can enable a different kind of conversation in the doctor’s office about treatment options.
Safety Considerations for Prescribers
Labeling under review includes warnings for insomnia, which developed in up to 60% of oveporexton-treated patients in pooled phase 3 studies versus 1% on placebo, and for urinary frequency and urgency, linked to OX2R agonism on central micturition pathways. Asymptomatic creatine phosphokinase elevations greater than 5 times the upper limit of normal were also observed more often with oveporexton than placebo.
Related: Trump pushes hospitals to release ER data
Because oveporexton has potential for abuse and misuse, its controlled substance classification is under DEA review, with a decision expected within 90 days of the FDA approval. Once scheduling is finalized, Orzeyful will be distributed through a specialty pharmacy to US health care providers and patients with NT1.
In practice, this development may mean that people with NT1 can experience improved wakefulness and reduced cataplexy, allowing them to better manage their daily lives. The introduction of oveporexton as a treatment option may also lead to increased awareness and understanding of NT1, potentially reducing the stigma associated with the condition.
As research continues to uncover the complexities of NT1, the approval of oveporexton marks a significant step forward in addressing the underlying causes of the disease. Takeda is developing additional orexin agonists, including TAK-360 for NT1, narcolepsy type 2, and idiopathic hypersomnia, and TAK-495. For more information on narcolepsy, people can visit the National Institute of Neurological Disorders and Stroke website.
